Clinical Trial Update: Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity and safety study of GSK's 208136 vaccine formulated with new seed strains for measles and rubella; results posted after completion. Condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• GSK 208136 vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Measles, Varicella | Phase 2 | Status: COMPLETED | Results posted: 2017-10-09